Bosutninb after other TKI toxicity -pro
The risk of the same side effects from dasatinib to bosultiib is 50% for edema, and this siide-effect is significantly severe and could threaten respiration. Other side effects are less common.
Jorge E. Cortesetal, Letters to the Editor: Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study. Haematologica Vol. 108 No. 12 (2023): December, 2023
Cortes JE, Apperley JF, DeAngelo DJ, Deininger MW, Kota VK, Rousselot P, Gambacorti-Passerini C. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. J Hematol Oncol. 2018 Dec 27;11(1):143. doi: 10.1186/s13045-018-0685-2. PMID: 30587215; PMCID: PMC6307238.
Bosutinib Prescribing Information 2025